SLCO2A1 and colitis: This hypothesis was proven true by administering mice MCC950, a specific inhibitor of the NLRP3 inflammasome24,38, as MCC950 administration reduced the severity of colitis in Slco2a1-deficient mice via suppressing the expression of mature IL-1β and cleaved caspase-1.